Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases
Patents cover a polymorph (crystalline form) of PTD802, Pheno's lead clinical candidate, and a composition of matter covering PTD939, Pheno's second GPR17 antagonist PTD802, a small molecule therapeutic designed to promote remyelination in neurological and neuCalla Lily Clinical Care awarded Innovate UK grant to expand Callavid platform for vaginal microbiome health
£700k Growth Catalyst award supports adaptation of Callavid intravaginal drug delivery platform for live biotherapeutic products and probioticsProgramme addresses pressing need for new approaches to vaginal dysbiosis conditions and supports efforts to tackle antimicrobiEnterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001
Investigational inhaled ENaC blocker developed to treat people with cystic fibrosis not benefitting from CFTR modulatorsPositive opinion recognises potential of ETD001 in treating rare and severe diseaseDecision follows successful Phase 2 clinical triaTRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.Includes up to $32 million in upfront and research milestone payments, withLaverock Therapeutics appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman
Appointment of experienced transatlantic leadership team, based in London and New York, to support lead programmes’ progression into the clinicInterim Chair Lisa Deschamps to transition to Non-Executive Director roleDavid Venables will step down as ChiPlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centres
PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centre
T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford
Newly built facility delivered by Kadans Science Partner at Barton House will support company growth and progression of novel T cell engager pipeline programmes
Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy
Preclinical proof-of-concept data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3 - 6 December 2026Data demonstrate that MOGRIFY-derived transcription factors can preserve and restore functional vision in a rodent model of photoreceptor degenLab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility
· New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required
· Suite of AI functions address key data bottlenecks in biological research labs, from protocol writing to equipment set-up
BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK
Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEsEnhances BioUK’s support offerings with SEHTA’s broad membership network and competencies in market accesCombat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study
Retrospective study evaluated the efficacy and safety of HIVEC® with mitomycin C in patients treated at the Erasmus Medical Center and Amphia hospital between 2015 and 2022Real-world data support HIVEC® as a bladder-preserving alternative to radicaQureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patientsAnnouncement comes after a recent European RespiraAmphista Therapeutics to present AMX-883 data at American Society of Hematology (ASH) Annual Meeting
AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and prelBio-Rad expands Precision Oncology Research Portfolio for Advanced Molecular Analysis Workflows
Expanded Portfolio Includes New Droplet Digital™ PCR Assays, Reagents and Technologies to Support Oncology Research Applications and Extend the Capabilities of the QX700™ ddPCR™ Systems
Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials
Peer-reviewed Viewpoint ‘Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials’ presents argument for measuring both lung function and fibrosis extent in antifibrotic trialsEvaluation of evidence from multiple studies positions fibrCuriox Biosystems strengthens commercial leadership to expand adoption of centrifuge-free sample preparation
Curiox Biosystems Inc (Curiox), a provider of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced the expansion of its senior commercial team and the formation of a Strategic Advisory Board (SAB).
Atelerix and Frontier Space partner to enable biological sample preservation for space missions
Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufact
BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the Life Sciences
Abingdon, UK - BioUK, the not-for-profit membership organisation focused on catalysing success in UK life sciences, announces the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London.
Eppendorf and BioLabs expand collaboration to support biotech innovation in Munich
• The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies • Builds on existing partnerships at BioLabs sites across the US, Germany and France
Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies
Trusted NGS chemistries from Takara Bio now optimized for firefly® automated workflows
ScionxBio announces collaboration to develop long-acting xRNA Therapeutics
Cambridge, UK, 20 October 2026: ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd.
Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands
Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models Joint poster at CHEST 2026 presents analysis completed as part of Qureight’s work on Celea’s phase 2b ELEVATE-ILeading life science organisations collaborate for second London Bio-Innovation Week
One Nucleus, SLAS, and ELRIG will connect their communities through cross-event networking and partnering opportunities during London Bio-Innovation WeekUndecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery
· A spin-out focused on AI-enabled decoding of the deliverome
· Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease